U.S. stock markets surged on Tuesday driven by reports of potential de-escalation in the Iran conflict, while Eli Lilly announced a major acquisition to expand into sleep disorder treatments.
Market Rally Fueled by Iran News
- The S&P 500 jumped over 2% following unconfirmed reports that Iranian President Masoud Pezeshkian is open to ending the war with certain guarantees, alongside a Wall Street Journal report on President Trump's willingness to de-escalate without reopening the Strait of Hormuz.
- WTI crude oil dropped approximately 1% but remained above $100 per barrel.
Eli Lilly's $7.8 Billion Sleep Disorder Acquisition
- Eli Lilly announced the acquisition of Centessa Pharmaceuticals, a clinical-stage company, in a deal worth up to $7.8 billion.
- Centessa's key asset is cleminorexton, a drug targeting excessive daytime sleepiness conditions like narcolepsy and idiopathic hypersomnia, with promising Phase 2a results.
- Analysts forecast peak sales exceeding $3 billion for cleminorexton if approved for all targeted indications, noting the deal broadens Lilly's neuroscience focus beyond obesity and diabetes.
Competitive and Analyst Highlights
- Novo Nordisk launched a subscription program with lower prices for Wegovy, intensifying competition in the GLP-1 market.
- Truist initiated coverage of Corning with a hold rating and $125 price target, citing valuation concerns despite positive momentum in its optical and solar segments.
- Nvidia formed a strategic partnership with Marvell on silicon photonics, signaling confidence in fiber optics for data centers.
Upcoming Earnings and Economic Data
- Earnings reports: Nike after market close Tuesday; Lamb Weston and Conagra before market open Wednesday.
- Economic indicators: ADP private payrolls for March, February retail sales data, and ISM manufacturing index for March.